EXPRESSION ANALYSIS OF P53, BCL-2 AND CYCLIND1 IN DIFFUSE LARGE B CELL LYMPHOMA PATIENTS

Objective: To investigate the value of evaluating the extent of coronary atherosclerosis in coronary heart disease (CHD) by apolipoprotein B Objective: To study the clinical significance of gene variations in P53, Bcl-2 and cyclin D1 in diffuse large B cell lymphoma (DLBCL). Methods: A total of 74 patients with DLBCL admitted to our hospital from July 2012 to June 2017 were selected. Clinical data from these patients were collected, and interphase fluorescence in situ hybridization (I-FISH) was performed to detect gene variations in P53, Bcl-2 and cyclin D1. The relationship between gene variation and therapeutic effects, international prognosis index (IPI), progression free survival (PFS) and overall survival (OS) was analyzed. Results: Among the patients, 29 (39.19%) had p53 gene deletion, 43 (58.11%) had Bcl-2 gene rearrangement, and 23 (31.08%) had CyclinD1 gene amplification or rearrangement. The rate of abnormalities in the genes Bcl-2 and CyclinD1 in patients with germinal center B-cell-like GCB was significantly higher than that in non-GCB patients (p < 0.05). Gene mutations in P53, Bcl-2 and cyclin D1 were closely related to clinical efficacy, IPI, FBS, OS and other indexes (p < 0.05). Conclusion: Mutations in the tumor-associated genes P53, Bcl-2 and cyclin D1 in DLBCL are closely related to the treatment and prognosis of DLBCL, and they have important value in guiding clinical decisions.